奥赛康(002755) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥770,191,659.64, a decrease of 36.43% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2021 was ¥128,845,289.89, down 48.71% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥124,985,905.30, a decrease of 47.38% compared to the previous year[4]. - Total operating revenue for the current period is ¥2,444,241,273.64, a decrease of 9.9% from ¥2,713,795,914.26 in the previous period[25]. - Net profit for the current period is ¥386,199,758.52, a decrease of 19.2% compared to ¥477,856,155.95 in the previous period[28]. - The company reported a total comprehensive income of ¥385,160,908.59, down from ¥477,199,275.93 in the previous period[31]. - Basic and diluted earnings per share are both ¥0.42, down from ¥0.52 in the previous period[31]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,667,739,337.83, a decrease of 3.69% from the end of the previous year[4]. - As of September 30, 2021, the total assets amounted to ¥3,667,739,337.83, a decrease from ¥3,808,099,396.51 on December 31, 2020[15]. - The total current assets were ¥2,472,244,856.40, down from ¥2,646,909,755.68 in the previous year[18]. - The company's cash and cash equivalents decreased to ¥846,224,705.77 from ¥1,369,098,462.16 year-over-year[15]. - Accounts receivable stood at ¥519,160,660.46, a decline from ¥713,868,272.54 in the previous period[18]. - The total liabilities decreased to ¥433,871,779.61 from ¥774,891,361.56 year-over-year[21]. - The total equity attributable to shareholders increased by 6.82% to ¥3,233,640,584.63 compared to the end of the previous year[4]. - The total equity attributable to shareholders increased to ¥3,233,640,584.63 from ¥3,027,151,332.35[24]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥281,063,579.72, down 33.74% compared to the same period last year[4]. - Cash inflow from operating activities totaled ¥3,041,298,586.72, a decrease of 6.0% from ¥3,235,960,554.75 in the previous period[32]. - The net cash flow from operating activities was 281,063,579.72, a decrease of 33.7% compared to 424,155,685.49 from the previous period[35]. - Cash outflow from investing activities totaled 1,620,003,595.27, significantly higher than 213,337,608.27 in the prior period[35]. - The net cash flow from investing activities was -588,243,595.27, worsening from -103,290,961.97 in the previous period[35]. - Cash outflow from financing activities was 215,688,346.33, compared to 205,975,436.93 in the prior period, indicating an increase[35]. - The net cash flow from financing activities was -215,688,346.33, compared to -183,329,049.03 previously, reflecting a decline[35]. - The ending balance of cash and cash equivalents was 843,098,931.28, down from 1,321,726,121.04 in the previous period[38]. - The company reported a total cash outflow of 522,873,756.39, contrasting with a cash inflow of 137,512,995.51 in the prior period[35]. Research and Development - The company's R&D expenses increased by 45.74% to ¥245,165,221.78, reflecting a greater investment in biopharmaceuticals and innovative drug development[10]. - Research and development expenses increased to ¥245,165,221.78, up 45.8% from ¥168,219,113.30 in the previous period[25]. - The company plans to continue focusing on R&D to drive future growth despite the current decline in revenue[28]. Strategic Initiatives - The company is focusing on expanding its market presence and developing new products and technologies[20]. - There are indications of potential mergers and acquisitions as part of the company's growth strategy[20]. Other Financial Metrics - The weighted average return on equity was 4.07%, a decrease of 5.36% year-on-year[4]. - The company reported a significant increase in other receivables, which rose by 312.22% to ¥102,188,222.55, primarily due to project guarantee deposits[10]. - The company has a significant decrease in accounts payable, which fell to ¥53,385,537.91 from ¥95,292,311.58[21]. - Other income increased to ¥9,936,736.70, up from ¥5,202,059.67 in the previous period[25]. - Investment income rose to ¥8,430,868.17, compared to ¥2,689,942.79 in the previous period[25]. - The cash paid to employees was 216,877,816.53, an increase from 195,365,958.98 in the previous period[35]. - The cash paid for taxes was 359,470,959.15, up from 294,058,773.38 in the previous period, indicating a rise in tax obligations[35]. - The cash received from investment recoveries was 1,031,200,000.00, a significant increase from 110,000,000.00 in the previous period[35].